Targeting cellular adhesion molecules, chemokines and chemokine receptors in rheumatoid arthritis.
The development of specific targeted therapies, such as anti-TNF-alpha treatment, for chronic inflammatory disorders such as rheumatoid arthritis, has significantly improved treatment, although not all patients respond. Targeting cellular adhesion molecules and chemokines/chemokine receptors as regulators of the extravasation and migration of leukocytes may provide a novel approach for the treatment of these diseases. Moreover, the possibility of developing small-molecule antagonists offers an excellent method for the oral delivery of compounds with a short half-life.
Haringman
Jasper J
JJ
Division of Clinical Immunology and Rheumatology F4-218, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, NL-1105 AZ, Amsterdam, The Netherlands.
Oostendorp
Roos L
RL
Tak
Paul P
PP
D000818:Animals; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000378:metabolism; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism; D015815:Cell Adhesion Molecules / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology; D018925:Chemokines / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D019707:Receptors, Chemokine / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*
D018501:Antirheumatic Agents; D015815:Cell Adhesion Molecules; D018925:Chemokines; D019707:Receptors, Chemokine